Last update Aug. 23, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Oxymetazoline Hydrochloride is also known as
Oxymetazoline Hydrochloride in other languages or writings:
Oxymetazoline Hydrochloride belongs to these groups or families:
Main tradenames from several countries containing Oxymetazoline Hydrochloride in its composition:
|Tmax||0.1 - 0.2||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Sympathomimetic with alpha adrenergic activity. It has a vasoconstrictor effect that reduces edema and congestion of the mucous membranes.
Topical nasal spray (2 times a day) or ophthalmic (3 - 4 times a day).
It is also used in facial cream to treat rosacea (Kuang 2018) and, mixed with local anesthetics, in dental anesthesia.
At the date of the last update, no published data was available in relation to breastfeeding.
The small dose and poor plasma absorption of most topical nasal, dermal, or ophthalmic preparations make it unlikely that a significant amount will pass into breast milk.
Measured plasma concentrations of oxymetazoline are low and its systemic effects are not clinically significant at the usual doses (Cartabuke 2019, Kuang 2018, Cacek 2017, Giannakopoulos 2012), so significant concentrations in milk are not to be expected.
Do not exceed the recommended dose and time to avoid undesirable side effects and the possible decrease in breast milk alluded to by some authors (Nice 2000), but not proven in practice.
Expert authors consider the use of this medication safe and probably compatible during breastfeeding (Hale 2019, Briggs 2017, Anderson 2000).
Ophthalmic administration is fully compatible with breastfeeding. Absorption can be minimized by pressing the tear duct (inner corner of the eye) with a finger for 1 minute.
Some authors consider oral and nasal decongestant drugs dispensable drugs, to be avoided in general, not only during lactation, since they expose patients to serious risks (cardiovascular, neurological and intestinal) to treat a benign disorder such as nasal obstruction, which usually progresses favorably within a few days without medication (Prescrire 2018).
A mother reported us irritability and insomnia for about 6 hours in her 7-month-old infant when she took oxymetazoline.